Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 [Yahoo! Finance]
Evaxion Biotech A/S - American Depositary Share (EVAX)
Company Research
Source: Yahoo! Finance
Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01's already strong data package COPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with AI-designed personalized cancer vaccine EVX-01. The data was presented today in a poster session at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting taking place in National Harbor, Maryland. Developed with Evaxion's AI-Immunology™ platform, EVX-01 is designed to target multiple neoantigens - cancer unique proteins arising from mutations - and to induce a clinically relevant immune response. The new biomarker and immune data stems from the phase 2 trial evaluating EVX-01 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, K
Show less
Read more
Impact Snapshot
Event Time:
EVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVAX alerts
High impacting Evaxion Biotech A/S - American Depositary Share news events
Weekly update
A roundup of the hottest topics
EVAX
News
- Evaxion expands AI-Immunology™ platform into autoimmune diseasesGlobeNewswire
- Evaxion A/S (NASDAQ:EVAX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next weekGlobeNewswire
- Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 [Yahoo! Finance]Yahoo! Finance
- Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2GlobeNewswire
EVAX
Sec Filings
- 1/13/26 - Form 6-K
- 1/7/26 - Form 6-K
- 12/19/25 - Form 6-K
- EVAX's page on the SEC website